Lotus
3
3M
2
0.33
- Areas of investment
Summary
Deals in the range of 5 - 10 millions dollars are the general things for fund. The fund is constantly included in less than 2 investment rounds annually. The high activity for fund was in 2004.
The usual cause for the fund is to invest in rounds with 9 partakers. Despite the Lotus, startups are often financed by Novartis Venture Fund, Alta Partners, Lombard Odier. The meaningful sponsors for the fund in investment in the same round are Novartis Venture Fund, JAFCO Japan, HBM Partners. In the next rounds fund is usually obtained by Novartis Venture Fund, JAFCO Japan, HBM Partners.
This organization was formed by Mitchell Kapor.
Besides, a startup needs to be aged 6-10 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Therapeutics, Biopharma. Among the most popular portfolio startups of the fund, we may highlight AGY Therapeutics, AGY Therapeutics.
Investments analytics
Analytics
- Total investments
- 3
- Lead investments
- 0
- Follow on index
- 0.33
- Investments by industry
- Gaming (2)
- Computer (2)
- Genetics (1)
- Medical (1)
- Biotechnology (1) Show 2 more
- Investments by region
-
- United States (1)
- Japan (2)
- Peak activity year
- 2017
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 16
- Group Appearance index
- 0.33
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| AGY Therapeutics | 07 Aug 2004 | Biotechnology, Genetics, Medical, Therapeutics, Biopharma | Late Stage Venture | 9M | United States, California, San Francisco |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.